Sarani, N.; Dasgupta, A.; Enders, M.; Rowan, L.; Elsarraj, H.; Gralnek, S.; Shay, M.; Lemar, L.R.; Simpson, S.Q.; Cunningham, M.T.;
et al. Clinical Utility of Recently Food and Drug Administration-Approved IntelliSep Test (Sepsis Biomarker) for Early Diagnosis of Sepsis: Comparison with Other Biomarkers. J. Clin. Med. 2024, 13, 4852.
https://doi.org/10.3390/jcm13164852
AMA Style
Sarani N, Dasgupta A, Enders M, Rowan L, Elsarraj H, Gralnek S, Shay M, Lemar LR, Simpson SQ, Cunningham MT,
et al. Clinical Utility of Recently Food and Drug Administration-Approved IntelliSep Test (Sepsis Biomarker) for Early Diagnosis of Sepsis: Comparison with Other Biomarkers. Journal of Clinical Medicine. 2024; 13(16):4852.
https://doi.org/10.3390/jcm13164852
Chicago/Turabian Style
Sarani, Nima, Amitava Dasgupta, Maria Enders, Lauren Rowan, Hanan Elsarraj, Sarah Gralnek, Madison Shay, Lucas R. Lemar, Steven Q. Simpson, Mark T. Cunningham,
and et al. 2024. "Clinical Utility of Recently Food and Drug Administration-Approved IntelliSep Test (Sepsis Biomarker) for Early Diagnosis of Sepsis: Comparison with Other Biomarkers" Journal of Clinical Medicine 13, no. 16: 4852.
https://doi.org/10.3390/jcm13164852
APA Style
Sarani, N., Dasgupta, A., Enders, M., Rowan, L., Elsarraj, H., Gralnek, S., Shay, M., Lemar, L. R., Simpson, S. Q., Cunningham, M. T., & Zheng, X. L.
(2024). Clinical Utility of Recently Food and Drug Administration-Approved IntelliSep Test (Sepsis Biomarker) for Early Diagnosis of Sepsis: Comparison with Other Biomarkers. Journal of Clinical Medicine, 13(16), 4852.
https://doi.org/10.3390/jcm13164852
